logo

XFOR

X4 Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
5.27 / 10
Netural

Capital flows are robust (score 7.43/10), with overall inflow ratio at 0.4486 and negative trend flags across block, small, medium, large, and extra-large patterns. This liquidity cushion may support the stock in the short term. Analyst coverage is minimal—only one active analyst issues a Strong Buy rating with 100% historical win rate, but the broader consensus is neutral. The mismatch between positive fund flow and neutral analyst outlook underscores the need for vigilance; without stronger buy-side conviction or technical confirmation, upside momentum could stall.

FundamentalSentiment(5.27)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

100%

Buy

0%

Hold

0%

Sell

0%

Strong Sell

0%

Date2025-12-05
InstitutionStifel
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for XFOR?
  • XFOR holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.27/10 (Netural).